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Dear Editor,
I read the recently published paper on Bcl-2 with great interest.1 
Hallack Neto et al. concluded that “Bcl-2 protein was expressed in 37% 
of the high-risk DLBCL patients, without any difference between the 
ABC-like DLBCL and GCB-like DLBCL cases.1” Indeed, the clinical 
value of determining Bcl-2 in B-cell lymphoma is still controversial. 
However, there are some problems in this work. The retrospective cohort 
design is not a common approach. There is also no risk classification 
from the analysis. The small number of subjects in this work might 
not be statistically acceptable for any conclusion.
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To the Editor
We would like to thank you very much for your attention to and 
comments on our trial published in issue 128(1) of this journal. As 
we ourselves acknowledged in the last paragraph of the discussion, 
the retrospective design of this trial and the small number of patients 
should be seen as questionable features and, therefore, our results need 
to be confirmed in a prospective study with more patients. However, 
despite the low statistical power of retrospective studies, the most 
important point is that such studies should be performed in order to 
raise questions and hypotheses for which proof may subsequently be 
obtained in trials with greater statistical power, in the way provided by 
prospective controlled trials. 
Concerning the observation about the absence of risk classifica-
tion from the analysis, we would like to clarify that, as described in 
the Methods section, all the patients enrolled in our trial were classi-
fied as intermediate-high and high risk according to the International 
Prognostic Index (IPI). 
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